Cardiac Valve Market Share

Rise in burden exerted by valvular heart diseases is driving the Heart Valves market growth

Increased geriatric population, shift in people's lifestyles from active to sedentary, novel developments in heart valves, increased awareness of surgical treatment options, and rising demand for minimally invasive surgeries are all factors driving the market's expansion. For instance, the American College of Cardiology estimates that every year, heart valve disease affects about 5 million Americans. However, some of the key constraints inhibiting the market's growth include the high cost of cardiac valves and the availability of other solutions for treating heart valve illness.

Another significant factor influencing the heart valve repair and replacement market is the ability of computational tools to mimic additional fluid mechanics properties like pressure decreases, regurgitation volumes, or turbulence. Additionally, the availability of computational techniques enables precise diagnosis of valvar illness, which results in effective therapy and expands the market for cardiac valve repair and replacement.

The market for Cardiac Valve devices and equipment has been driven by the growing demand for transcatheter aortic valve replacement (TAVR) procedures as the prevalence of valvular heart disease has increased. The aortic valve of the heart is impacted by the valvular heart ailment known as aortic stenosis. A minimally invasive surgical procedure used to treat it is called TAVR. The aortic valve stiffens as a result of aortic stenosis, obstructing normal blood flow. The damaged aortic valve is replaced using a transcatheter valve.

The Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) TVT Registry study found that volumes had risen annually. 2019 marked the first year that TAVR overcame all variations of surgical aortic valve replacement (SAVR). The number of TAVR performed each year is rising in accordance with the FDA's clearance of the procedure for low-risk patients, and in 2019 the overall volume of TAVR (72,991) surpassed all other types of SAVR (57,626).

The frequency of TAVR surgeries will probably increase along with the prevalence of valvular heart disease, which will lead to a rise in the demand for transcatheter valves and, in turn, a rise in the market for cardiac valves.

The rising incidence of heart valve illness and the rising number of novel and improved cardiac valves receiving regulatory approvals are the key drivers driving the market's expansion. The market is expanding as a result of the rising incidence of heart valve disease, which is a significant component. For instance, rheumatic heart disease affects 39 million people worldwide, according to the World Heart Federation 2022. It is a condition when rheumatic fever has permanently affected the heart valves. Thus, driving the Cardiac Valve market revenue.

The global demographic shift towards an aging population is a significant factor influencing the Global Cardiac Valve Market Industry. As individuals age, the risk of developing heart-related conditions escalates, leading to a higher demand for cardiac interventions. By 2035, it is anticipated that the number of individuals aged 65 and older will reach approximately 1.1 billion worldwide. This demographic trend underscores the necessity for effective cardiac valve solutions, as older adults are more likely to require valve replacements or repairs. Consequently, the market is poised for substantial growth, driven by the increasing prevalence of age-related cardiovascular issues.

The upward trend in global healthcare spending is a crucial driver for the Global Cardiac Valve Market Industry. Governments and private sectors are increasingly investing in healthcare infrastructure, which includes advanced cardiac care facilities. This investment facilitates access to innovative cardiac valve treatments and technologies. For instance, countries with robust healthcare systems are more likely to adopt new surgical techniques and devices, enhancing patient care. As healthcare expenditure continues to rise, the demand for cardiac valve interventions is expected to increase, further propelling market growth. This trend aligns with the projected market value of 8.2 USD Billion in 2024, indicating a strong financial commitment to addressing cardiovascular health.

Heightened awareness of cardiovascular health and the implementation of screening programs are pivotal in driving the Global Cardiac Valve Market Industry. Public health initiatives aimed at educating populations about heart health have led to earlier diagnosis and treatment of cardiac conditions. Screening programs facilitate the identification of individuals at risk, allowing for timely interventions. This proactive approach not only improves patient outcomes but also contributes to the overall growth of the cardiac valve market. As awareness continues to rise, the demand for cardiac valve replacements and repairs is likely to increase, supporting the projected growth trajectory of the industry.

Innovations in cardiac valve technology are transforming the Global Cardiac Valve Market Industry. The development of minimally invasive surgical techniques and advanced materials has led to the creation of more durable and biocompatible valves. For instance, transcatheter aortic valve replacement (TAVR) has gained popularity due to its reduced recovery time and lower complication rates. These advancements not only improve patient outcomes but also expand the treatment options available for healthcare providers. As a result, the market is likely to experience robust growth, with a projected compound annual growth rate of 5.62% from 2025 to 2035, reflecting the increasing adoption of these cutting-edge technologies.

The increasing incidence of cardiovascular diseases globally is a primary driver of the Global Cardiac Valve Market Industry. According to health statistics, cardiovascular diseases remain the leading cause of mortality worldwide, accounting for approximately 31% of all deaths. This alarming trend necessitates advanced treatment options, including cardiac valve replacements and repairs. As the population ages and lifestyle-related risk factors rise, the demand for effective cardiac interventions is expected to surge. This growing need is projected to contribute significantly to the market, with estimates suggesting a market value of 8.2 USD Billion in 2024, potentially reaching 15.0 USD Billion by 2035.

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Cardiac Valve market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Cardiac Valve industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  Cardiac Valve industry to benefit clients and increase the market sector. In recent years, the Cardiac Valve industry has offered some of the most significant advantages to medicine. Major players in the Cardiac Valve market, including Medtronic, Edwards Lifesciences Corporation, Boston Scientific Corporation, LivaNova PLC, Abbott, CryoLife, Inc, On-X Life Technologies, Inc., Colibri Heart Valve, JenaValve Technology, Inc., and TTK HealthCare, are attempting to increase market demand by investing in research and development Products.

An organisation that develops, produces, and markets devices for structural heart disease, critical care, and surgical monitoring is called Edwards Lifesciences Corp (Edwards Lifesciences). The company sells transcatheter heart valves, pressure monitoring equipment, hemodynamic monitoring equipment, surgical valve replacement and repair devices, as well as other tools and accessories. The management of clotting, hypotension, and sepsis, as well as transcatheter aortic valve replacement (TAVR), blood conservation, infection control, and improved surgical recovery are just a few therapies that its products are used in.

The business sells its goods directly to consumers as well as through a network of independent distributors in regions like North America, Europe, and Asia-Pacific. The American city of Irvine serves as the headquarters of Edwards Lifesciences. The MITRIS RESILIA valve was approved by the US Food and Drug Administration (FDA) in March 2022 for Edwards Lifesciences. It is a tissue valve replacement made especially for the mitral location of the heart.

The mission of JenaValve Technology, Inc., a developer and producer of transcatheter aortic valve replacement (TAVR) systems, is to enhance the quality of life for people with structural heart diseases. Because of an anatomically based locator fixation and dual sealing valve design, the company's technology uses porcine pericardial tissue and a self-expanding nitinol frame with a transfemoral delivery system that does not require rapid pacing. This enables patients with ease of use, decreased risks of paravalvular regurgitation, and durability of hemodynamic results.

With the Chinese company Peijia Medical Limited, JenaValve Technology, Inc. engaged into a strategic investment and exclusive technology licencing deal in January 2022.